Overview
Study Comparing the Safety and Efficacy of Two Doses of BC-3781 vs Vancomycin in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)
Status:
Completed
Completed
Trial end date:
2011-02-03
2011-02-03
Target enrollment:
0
0
Participant gender:
All
All
Summary
This is a Phase II, multi-center, randomized, double-blind study comparing the safety and efficacy of two doses of BC-3781 versus vancomycin in patients with acute bacterial skin and skin structure infection.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Nabriva Therapeutics AGTreatments:
Lefamulin
Vancomycin
Criteria
Inclusion Criteria:- Male or female patients > 18
- Documented acute bacterial skin and skin structure infection
Exclusion Criteria:
- Uncomplicated skin and skin structure infection